Product Overview
Xeno Tirzepatide is a 10 mg vial of lyophilised peptide. The molecule is a lipidated 39 amino acid chain that activates two incretin receptors, GIP and GLP-1, rather than one, and that dual action is the main pharmacological difference between it and the single-receptor GLP-1 products.
It is supplied in the research format. The approved prescription versions are pre-filled pens with a fixed dose per step, and the difference matters: a vial leaves reconstitution, concentration and sterility to the user, and regulators have warned specifically about unapproved versions of this class.
Mixing and Weekly Arithmetic
Bacteriostatic water dissolves the powder and the fill decides the strength. Put the 10 mg fill into 5 ml and every millilitre holds 2 mg, so a ten unit draw on a U-100 barrel delivers 200 micrograms. Use 10 ml of diluent instead and the solution is 1 mg per ml, so the same draw delivers only 100 micrograms. Since the reference doses are written in milligrams per week, that factor of two is worth writing down.
Keep the powder refrigerated and the solution at 2-8 C, used within weeks and never frozen. Because the half-life is about five days, the weekly interval is comfortable and a missed day does not collapse the level, but the accumulation over weeks is why effects build slowly rather than in a rush.
Trial Dose Ladder
The reference ladder comes from the approved product and the SURMOUNT-1 programme. It is presented as a scale for the medicine, not as a protocol for the vial.
| Start | 2.5 mg a week for at least 4 weeks, a tolerability step rather than a treatment dose |
| Second step | 5 mg a week, held for 4 weeks, where the trial effect was already clear |
| Upper steps | Up to 10 mg and 15 mg weekly by tolerance, the ceiling of the SURMOUNT-1 range |
| Female | Identical steps beginning at 2.5 mg; the sources give no separate protocol for women |
| Administration | Subcutaneous once a week; a five-day half-life supports the weekly interval |
In that programme average weight change at 72 weeks was around minus 15 percent at 5 mg and up to minus 20.9 percent at 15 mg against minus 3.1 percent on placebo, with discontinuation for adverse effects rising as the dose climbed, from about 5 percent at 5 mg to roughly 25 percent at the highest step. Both halves of that sentence matter.
Suggested Protocols
- Slow titration is the whole protocol. Gastrointestinal tolerability and the dropout rate both follow the speed of escalation rather than the final dose.
- Compare the two incretin routes. The Semaglutide page covers the single-receptor option, which is dosed on a different step scale.
- Protect lean mass. Protein targets and resistance training are the practical counterweight to appetite suppression so deep that intake falls below needs.
- Do not stack with another incretin. Adding a second GLP-1 agent duplicates the same mechanism and multiplies the gastrointestinal load.
- Plan the exit. Tapering rather than stopping abruptly is the pattern the sources describe, because appetite returns sharply at the top doses.
What to Expect
- Appetite drops within a week or two. The change is noticeable on the starting step, long before weight moves.
- Weight loss accumulates over months. The trial's main readout was at 72 weeks, which is why short cycles do not fit this class.
- Gastrointestinal effects arrive with each increase. They usually ease over one to two weeks if the tempo is not pushed.
- Food intake can fall too far. Under-eating protein and calories is a real risk and shows up in the composition of the weight lost.
- Pancreatitis and gallbladder events are rare class concerns. Severe abdominal pain warrants immediate medical attention.
- Stopping brings the weight back. Over half of the loss typically returns within a year without a maintenance plan.
Side Effects and Management
Stopping and Follow-up
The compound does not suppress the gonad axis, so a classical recovery block is not required. The end of treatment is about appetite returning and weight following it, which is why the follow-up list is metabolic.
Buying This Vial
Tirzepatide is listed in the Xeno Laboratories range beside Semaglutide, BPC-157 and Epitalon, and beside the injectable HCG 5000 IU and the metabolic support pages T3 and T4. Each page states fill weight, format and current availability.
The dual mechanism also explains the side-effect pattern more clearly than a generic description. Because both incretin receptors are engaged, gastric emptying slows and appetite signalling changes at the same time, which is why nausea, early fullness and reduced intake arrive together at the start of each step rather than one after the other. It does not follow that a higher step is a better one: the trial data show more discontinuations as the dose rises, so the middle of the ladder is where the balance usually lies.
